Homeobox protein Hox-D13 is encoded by HOXD13 gene which is frequently methylated in cancer and has been recognized as a tumor suppressor in pancreatic cancer. In this study, we examined HOXD13 mRNA expression in 40 pairs of breast cancers and corresponding normal breast tissues. Bisulfite sequencing of HOXD13 promoter was performed in 6 pairs of breast tumors and corresponding normal breast tissues to examine the potential HOXD13 CpG methylated sites. HOXD13 DNA methylation frequency analysis was performed using MethyLight in 196 pairs of breast cancers and corresponding normal breast samples. DNA methylation status and clinico-pathological features were investigated. Kaplan-Meier survival analysis and Cox proportional hazards models were utilized to assess the effect of methylation status on overall survival. We found that 60% (24/40) of breast cancers showed low HOXD13 mRNA expression when compared with corresponding normal breast tissue. The predicted CpG island was located in the -1325 bp to +675 bp region. Next, the -332 bp site in HOXD13 gene promoter was further examined and in 57.7% (113/196) samples methylation was detected at this site. HOXD13 methylation was correlated with larger tumor size (P = 0.004), but not with other clinico-pathological parameters. In addition, patients with methylated -HOXD13 promoter had worse overall survival (OS) (P = 0.005). Based on our results we conclude that HOXD13 methylation is a common event in primary breast cancer and is associated with poor survival of breast cancer patients. HOXD13 methylation could therefore potentially be used as a prognostic factor for breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637597 | PMC |
Publication Analysis
Top Keywords
Similar Publications
DNA methyltransferase inhibitors (DNMTi), most commonly cytidine analogs, are compounds that are used clinically to decrease 5'-cytosine methylation, with the aim of re-expression of tumor suppressor genes. We used a murine pre-clinical model of myelodysplastic syndrome based on transplantation of cells expressing a NUP98::HOXD13 transgene to investigate 5-Aza-4'-thio-2'-deoxycytidine (Aza TdCyd or ATC), a thiol substituted DNMTi, as a potential therapy. We found that ATC treatment led to lymphoid leukemia in wild-type recipient cells; further study revealed that healthy mice treated with ATC also developed lymphoid leukemia.
View Article and Find Full Text PDFThe Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
Cancer Res
March 2024
Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan.
Article Synopsis
- The study analyzed the epigenetic changes in gliomas from 132 patients over time, comparing initial and recurrent tumors in both IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) types.
- IDHwt gliomas remained stable in their epigenetic profile, while IDHmut gliomas showed a notable decrease in DNA methylation, making their profiles more similar to IDHwt tumors.
- The research identified HOXD13 as crucial for the evolution of IDHmut tumors and found that treatment led to changes in the tumor microenvironment, like increased blood vessel formation and T-cell presence, mimicking the characteristics of IDHwt gliomas.
PRC1 sustains the integrity of neural fate in the absence of PRC2 function.
Elife
January 2022
Neuroscience Institute, Department of Neuroscience and Physiology, NYU School of Medicine, New York, United States.
Polycomb repressive complexes (PRCs) 1 and 2 maintain stable cellular memories of early fate decisions by establishing heritable patterns of gene repression. PRCs repress transcription through histone modifications and chromatin compaction, but their roles in neuronal subtype diversification are poorly defined. We found that PRC1 is essential for the specification of segmentally restricted spinal motor neuron (MN) subtypes, while PRC2 activity is dispensable to maintain MN positional identities during terminal differentiation.
View Article and Find Full Text PDFMutant Cooperates with a Fusion to Induce Early Immature Thymocyte Precursor ALL.
Cancer Res
October 2021
Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.
Mutations in the isocitrate dehydrogenase 1 () and genes are frequently observed in a wide variety of hematologic malignancies, including myeloid and T-cell leukemias. In this study, we generated transgenic mice to examine the role of the mutation in leukemia. No leukemia developed in transgenic mice, suggesting a need for additional genetic events for leukemia development.
View Article and Find Full Text PDFDNA Methylation Profiles and Their Diagnostic Utility in BC.
Dis Markers
November 2019
Department of BC Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Biomarkers, including DNA methylation, have shown a great potential for use in personalized medicine for BC and especially for the diagnosis of BC in developing countries. According to the bisulfite sequencing PCR in twelve specimens (BC and matched normal tissues), nine genetic probes were designed to detect the frequency of methylation of the promoters in a total of 302 paired cases of BC and matched normal breast tissues. Finally, a total of 900 serum samples were used to validate the use of these methylation biomarkers for clinical diagnosis of BC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!